Related Experiment Videos
Prolonged liver-specific transgene expression by a non-primate lentiviral vector
Reba Condiotti1, Michael A Curran, Garry P Nolan
1Goldyne Savad Institute of Gene Therapy, Hadassah University Hospital, Jerusalem 91120, Israel. reba@hadassah.org.il
Biochemical and Biophysical Research Communications
|July 9, 2004
Summary
Feline immunodeficiency virus-based lentiviral vectors show promise for liver-directed gene therapy. These vectors enable stable, long-term gene expression in hepatocytes, offering a potential new treatment for metabolic diseases.
Area of Science:
- Gene Therapy
- Virology
- Hepatology
Background:
- Liver-directed gene therapy offers potential for inherited metabolic diseases.
- Lentiviral vectors (LVs) are being explored for gene delivery.
- Feline immunodeficiency virus (FIV)-based LVs may offer safety advantages over human immunodeficiency virus (HIV)-based LVs.
Purpose of the Study:
- To evaluate gene expression in hepatocytes using FIV-based lentiviral vectors.
- To assess the safety and efficacy of FIV-based LVs for liver gene therapy.
- To compare FIV-based LVs with plasmid DNA for gene delivery to the liver.
Main Methods:
- In vitro transduction of hepatocytes with FIV-based LVs.
- Assessment of gene expression stability and duration.
- Analysis of viral integration using Alu PCR and Southern blot.
- In vivo systemic administration via hydrodynamic injection in animal models.
Main Results:
- Stable gene expression in hepatocytes for up to 24 days in vitro.
- Evidence of viral integration into the host cell genome.
- High levels of exclusive liver gene expression for over 7 months in vivo following LV administration.
- Transient expression observed with plasmid DNA delivery via hydrodynamic injection.
Conclusions:
- FIV-based lentiviral vectors specifically transduce liver cells.
- These vectors demonstrate long-term gene expression in the liver.
- FIV-based LVs represent a promising novel gene delivery vehicle for treating metabolic diseases.